BULARREKO MINBIZIA
![Foto de BULARREKO MINBIZIA](/img/grupo.png)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaHospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (19)
2024
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Breast, Vol. 77
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
-
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
eClinicalMedicine, Vol. 71
2023
2022
-
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network
Cancers, Vol. 14, Núm. 8
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
-
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 6, pp. 1107-1116
2019
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2013
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2001
1998
-
Tratamiento del linfoma gástrico MALT de bajo grado con erradicación de Helicobacter pylori. Seguimiento de la respuesta histológica y molecular
Medicina Clinica, Vol. 110, Núm. 2, pp. 41-44
1997
-
Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori
Scandinavian Journal of Gastroenterology, Vol. 32, Núm. 4, pp. 303-307